CTI BioPharma Corp. (CTIC)

4.31
0.02 0.47
NASDAQ
Prev Close 4.29
Open 4.29
Day Low/High 4.29 / 4.35
52 Wk Low/High 0.25 / 1.94
Volume 8.54K
Exchange NASDAQ
Shares Outstanding 28.23B
Market Cap 117.42M
Div & Yield N.A. (N.A)

Latest News

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

Trial demonstrates statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib

Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting

Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting

-72 week follow up of patients with myelofibrosis, including patients with baseline thrombocytopenia, show pacritinib treatment led to durable reductions in spleen volume and symptom burden-

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Stocks with insider trader activity include LPNT, PATK and CTIC

CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting

CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting

- Four abstracts selected to be presented on pacritinib highlighting additional safety and long-term follow up data from Phase 3 PERSIST-1 trial -

CTI BioPharma Announces Presentations At The American Association Of Cancer Research Annual Meeting

CTI BioPharma Announces Presentations At The American Association Of Cancer Research Annual Meeting

- Five abstracts selected to be presented on pacritinib -

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming  April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Stocks with insider trader activity include SPTN, FL and CTIC

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - DRE And CTIC Traded By Insiders

Insider Trading Alert - DRE And CTIC Traded By Insiders

Stocks with insider trader activity include DRE, CTIC and WAFD